Abstract In this paper, we have evaluated the diagnostic utility of three antigenic regions of the Mycoplasma pneumoniae P1, P30, and MPN456 gene products in order to replace the soluble, whole-cell bacterial extract in serological assays. Antigenic regions, being previously identified as B-cell epitopes, were used individually or assembled in a recombinant chimeric antigen by genetic engineering. Paired serum samples from 47 patients with M. pneumoniae infection and from 39 subjects with a clinical picture of atypical pneumonia but without a defined diagnosis of M. pneumoniae infection were included. Immunoglobulin G (IgG) antibodies against epitopes carried by recombinant antigens were measured by performing recombinant enzyme-linked immunosorbent assays (Rec-ELISAs). Rec-ELISA results were compared to those obtained by a commercial assay using the wholecell Mycoplasma antigen. Our study demonstrates that all IgG Rec-ELISAs using recombinant antigens have better sensitivity with respect to the commercial assay. Furthermore, we show that the use of chimeric antigens improve the performance of the assays. The use of recombinant antigens is effective in distinguishing M. pneumoniae-infected patients from uninfected individuals and shows that immunoassays based on recombinant antigens could provide the basis for standardized commercial tests for the serodiagnosis of M. pneumoniae diseases.
Introduction
Mycoplasma pneumoniae is the leading cause of atypical pneumonia in children and young adults. It is responsible for 10-20% of cases of community-acquired pneumonia, giving rise to extrapulmonary complications in 25% of infected patients [1] [2] [3] .
Infected individuals show flu-like symptoms, but, characteristically, there is an insidious onset with chronic recovery [2, 4] . Misdiagnosis and subsequent inappropriate antibiotic treatment pose a serious threat to infected individuals [5, 6] . Although clinicians may suspect infections during epidemics, an etiological diagnosis cannot be formulated on the basis of clinical appearance, since other bacterial and viral infections often share symptoms and clinical features [2, 7] .
The diagnosis of M. pneumoniae infection can be established by isolating bacteria or detecting Mycoplasmaspecific DNA sequences and immunoglobulins in body fluids and sera from infected individuals, respectively. Serological methods play a predominant role in routine clinical practice, mainly due to the ease of specimen collection and the widespread availability of serologic tests [8] .
Host antibody response to M. pneumoniae infection can be detected after 1 week of illness, but it generally peaks 3 to 6 weeks after acute infection, followed by a gradual decay of antibody production over a period of months to years [1, 9] . As a result of the long incubation period, the antibody response is often evident by the time symptoms appear. A simultaneous testing for both IgG and IgM in paired serum samples collected 2 to 3 weeks apart is usually required to achieve a proper diagnosis.
The serodiagnosis of M. pneumoniae infection can be performed by the use of complement fixation (CF) tests, indirect immunofluorescent assays (IFAs), and enzymelinked immunoassays (EIAs) to detect the presence of the various classes of anti-Mycoplasma immunoglobulins (IgG, IgM) [9] . All of the commercially available assays use the whole M. pneumoniae-soluble extract or subcellular fractions as the antigen. However, these assays have limited sensitivity and specificity, since cross-reactions of the antigen with antibodies to other Mycoplasma species and other bacterial pathogens may occur [1] . Also, the available assays may vary in their ability to detect serum immunoglobulins [10, 11] , due to the lack of a purified standardized antigen or standard methods for preparing the antigen.
The aim of this study was to improve the performance of EIAs for the serodiagnosis of M. pneumoniae infection using recombinant antigens, which were tested with sera from a cohort of patients with respiratory tract diseases clinically compatible with "atypical" bacterial etiology. We have previously shown the identification and characterization of immunodominant B-cell epitopes of M. pneumoniae antigens using the phage display technology [12] . We show here the usefulness of recombinant proteins containing epitopes of the P1, P30, and MPN456 antigens in M. pneumoniae serodiagnosis.
Materials and methods

Cloning the chimeric antigen EC12
The DNA coding for the antigenic regions of M. pneumoniae P1 (residues 1307-1340), P30 (residues 194-241), and MPN456 (residues 765-846) open reading frames [12] were used for the construction of the chimeric antigen EC12. DNA fragments of P1 and MPN456 were amplified by polymerase chain reaction (PCR) from M. pneumoniae DNA, FH strain (DNA commercially available and purchased from ABIonline, Columbia, MD), using specific oligonucleotides as follows:
The PCR conditions were 30 s at 94°C, 30 s at 55°C, and 60 s at 72°C for 30 cycles. The PCR products of P1 and MPN456 fragments were purified, mixed, and then used as templates for DNA amplification using oligonucleotides P1-for and MPN456-rev. The PCR protocol was 30 s at 94°C, 30 s at 55°C, and 60 s at 72°C for 25 cycles. The resulting DNA was purified by standard methods and cloned into the plasmid pGEX-P30 [12] , which contained the antigenic region of the P30 antigen (amino acids 194-241) fused at the N-terminus of the GST protein, to generate the plasmid pGEX-EC12 (schematically shown in Fig. 1 ).
Purification of recombinant antigens
Four M. pneumoniae antigens were used: P1, P30, MPN456 [12] , and EC12. Recombinant antigens were expressed in bacterial cells as fusion proteins with glutathione S-transferase (GST) and purified by affinity chromatography as described previously [13] . Briefly, recombinant Escherichia coli strain AD202 were grown in Luria Bertani (LB) medium and gene expression was induced using isopropyl-β-D-thiogalactopyranoside (IPTG). Bacteria were centrifuged at 2,000g for 30 min at 4°C and then suspended in STE buffer (10 mM TrisHCl [pH 8.0], 150 mM NaCl) containing 100 μg mL −1 of lysozyme and protease inhibitors (Boehringer, Ingelheim, Germany). The mixture was sonicated and Triton X-100 was added to a final concentration of 1%. After centrifugation at 10,000g for 30 min at 4°C, the supernatant was incubated with glutathione-Sepharose beads (BD Biosciences, San Jose, CA) and the GST fusion proteins were eluted following the manufacturer's instructions and stored at −20°C. The recombinant antigens were efficiently expressed and purified in large amounts from the cytoplasm of bacterial cells, with a purity >90% and a yield of purified proteins of 5-15 mg per liter of bacterial cultures.
Serum samples
One hundred and eighty-four serum samples collected from 98 patients hospitalized for pulmonary diseases at the Clinic of Infectious Diseases of Siena University, Italy, during the period 1999 to 2005 were used. A clinical picture compatible with atypical pneumonia [2] was defined by the presence of the following features: insidious onset, malaise, fever, cough ≥1 week; signs of interstitial pneumonia ± wheezing; extra-pulmonary manifestations compatible with Mycoplasma infection (e.g., arthralgia, skin eruption); radiological findings suggestive of interstitial involvement ± minimal pleuritis; lack of responsiveness to previous beta-lactams therapy. pediatric patients affected by Streptococcus pneumoniae pneumonia and that resulted negative for M. pneumoniaespecific serology and PCR analysis Two sera were collected from each patient of groups A and B; the first sample at the time of recovery and the second after dismissing (usually 2-3 weeks after hospitalization).
Whole-cell Mycoplasma antigen immunoassays
Analysis of Mycoplasma-specific IgG antibodies were done by the whole-cell, Mycoplasma antigen assay ELISA-IgG (IBL, Hamburg, Germany), according to the manufacturer's instructions (e.g., sera diluted 1:100). All serum samples were analyzed in a blinded fashion.
Recombinant protein enzyme immunoassays (Rec-ELISA)
MaxiSorp plates (Nunc) were adsorbed with recombinant proteins at a concentration of 10 μg mL −1 in 50 mM NaHCO 3 , pH 9.6. Each protein (GST-P1, GST-P30, GST-MPN456, and GST-EC12) was coated separately onto individual microtiter wells. After incubation overnight at 4°C, the plates were blocked with 5% non-fat dry milk and 0.05% Tween 20 in PBS (blocking buffer) and subsequently incubated for 1 h at 37°C with serum samples diluted 1:100 in blocking buffer. The plates were washed with 0.05% Tween 20 in PBS and anti-human IgG alkaline phosphatase-conjugated antibodies (Sigma-Aldrich) were added to each well. Finally, incubating plates with the chromogenic substrate p-nitrophenylphosphate (pNPP; Sigma-Aldrich) revealed the enzymatic activity. The results were recorded as the difference between the absorbance (optical density, OD) at 405 nm and that at 620 nm, as detected by an automated ELISA reader (Labsystems Multiskan, Finland). For each serum, the assay was done in duplicate and average values were calculated. For every GST fusion product, the cutoff value was determined as the mean plus three times the standard deviation of the absorbance readings obtained from the Mycoplasma-negative sera (group C).
Statistical analysis
The sensitivity, specificity, and positive and negative predictive values of the ELISAs are given. Proportions were compared by the Chi-square test or Fisher's exact test (two-tailed), with a p-value <0.05 being considered as statistically significant. 
Results
In a retrospective study, 184 sera from 98 patients hospitalized for pneumonia were analyzed. Paired sera from 86 cases of atypical pneumonia were available and were further divided into two groups as follows: group A, from 47 subjects with a defined diagnosis of M. pneumoniae infection; group B from 39 subjects without a defined diagnosis of M. pneumoniae infection but with a clinical picture compatible with atypical pneumonia. Twelve sera from 12 patients affected by Streptococcus pneumoniae pneumonia with negative results for M. pneumoniae-specific serology and PCR analysis were also assayed as negative controls (group C). To set up an immunoassay based on recombinant antigens, three regions of the M. pneumoniae P1, P30, and MPN456 gene products, which had been shown previously to contain B-cell epitopes [12] , were chosen for the investigation. The antigen fragments were produced in E. coli as GST fusion products (namely, GST-P1, GST-P30, and GST-MPN456). Also, the antigenic regions of P1, P30, and MPN456 proteins were assembled to give the chimeric antigen GST-EC12 (Fig. 1) .
The immunoreactivity of GST-P1, GST-P30, GST-MPN456, and GST-EC12 with IgG antibodies in sera from patients with a defined diagnosis of M. pneumoniae infection (group A) was determined. Each of the antigens was coated separately in individual wells and tested in the IgG Rec-ELISAs with paired sera from the 47 subjects of group A (Table 1) . Overall, the proportion of IgG-reactive sera were 54, 48, 25, and 57% by use of recombinant GST-P1, GST-P30, GST-MPN456, and GST-EC12 antigens, respectively. None of the Mycoplasma-negative sera reacted with the GST fusion products. GST-MPN456, GST-P1, GST-P30, and GST-EC12 specifically reacted with IgG antibodies present in at least one of the paired sera from 40, 87, 81, and 94% of infected patients, respectively. Also, 40 out of 47 patients (85%) developed specific IgG antibodies against at least two distinct M. pneumoniae antigens during hospitalization.
Sera from group A patients were also analyzed with a commercial IgG ELISA assay, which employs the whole-cell extract of M. pneumoniae as the antigen (Table 1) . A low proportion of IgG-positive sera was observed (19%), allowing to obtain a correct diagnosis of M. pneumoniae infection in only 17 out of 47 infected patients (36.2%). Also, only 12 out of 59 serum samples having specific anti-Mycoplasma antibodies, as assessed by the CF test, were found to be positive with the commercial ELISA (patients A1-A39), allowing a positive diagnosis in only 12 out of 39 subjects (31%).
The performance of IgG assays employing the wholecell extract or recombinant antigens for the serological diagnosis of M. pneumoniae infection is summarized in Table 2 . All of the assays based on recombinant antigens showed a significantly better performance when compared to the commercial test. In particular, the assay based on the chimeric antigen EC12 revealed a significantly higher sensitivity with respect to the commercial assay (93.6% versus 36.2%, respectively; p<0.001).
Next, the immunoreactivity of recombinant antigens was assessed with IgG antibodies in sera from patients with a clinical picture of atypical pneumonia but without a defined diagnosis of M. pneumoniae infection (group B), and the results of Rec-ELISAs were compared with those obtained using the commercial assay. Detailed results of all IgG assays performed with paired sera collected from the 39 patients of group B are shown in Table 3 . Overall, 23 out of 78 sera specifically reacted with at least one recombinant antigen, allowing the serological diagnosis of M. pneumoniae infection in 13 patients (33%). In particular, a constant IgG titer towards GST-EC12 and other recombinant antigens was revealed in 5 patients (B2, B28-B31), while an increase of IgG titer towards single antigens and/or EC12 was revealed in 3 patients (B32-B34) with a negative diagnosis of M. pneumoniae infection on the basis of the CF assay and in 5 patients (B35-B39) who were not and sera from patients with pneumococcal pneumonia (n=12) checked for M. pneumoniae infection. By contrast, none of the sera displayed a positive result when the commercial assay was used.
Discussion
M. pneumoniae infection occurs endemically and epidemically worldwide; hence, it should be considered in the differential diagnosis of upper and lower respiratory tract diseases [1, 2, 9] . Moreover, M. pneumoniae colonization is believed to be strongly implicated in the pathogenesis and exacerbation of asthma, and it seems of certain concern in other chronic diseases [14] [15] [16] [17] [18] [19] [20] [21] . The clinical management of this "atypical" pathogen requires aimed therapy, but a standardized and rapid diagnostic test is lacking, due to inherent limitations of current microbiological, molecular, and serological assays [9] . The present study evaluated the diagnostic utility of serological assays employing recombinant proteins, composed of distinct antigenic regions of M. pneumoniae gene products. The main objective of our work was, therefore, the provision of "artificial antigens" and their use for the development of selective diagnostic immunoassays. Three distinct antigenic regions of M. pneumoniae proteins [12] were used individually (P1, P30, and MPN456) or further assembled into a chimeric product (EC12). By using a standard bacterial expression system, all recombinant antigens were purified under native condition in large amounts and were found to have good solubility and elevated purification yield, which are fundamental prerequisites for the commercial use of recombinant antigens. The immunoreactivity of EC12 as well as the single antigenic regions composing the chimera was assessed with IgG antibodies present in sera from patients hospitalized for M. pneumoniae infection. All IgG assays employing recombinant antigens showed excellent sensitivity and specificity, with the EC12-based assay reaching the best sensitivity (93.6%), based on the available sera used in this study. The results of the chimeric antigen immunoassay were in agreement with those obtained using the CF assay, since 92% of the patients who received a positive diagnosis by the CF analysis were found to be positive in the EC12 Rec-ELISA.
The results of the CF test were also compared to those obtained with a commercial assay which utilizes the whole M. pneumoniae cell extract as the antigen. Surprisingly, only 31% of subjects having specific anti-Mycoplasma antibodies, as measured by the CF test, were found to be positive by the commercial ELISA.
The immunoreactivity of recombinant antigens was then investigated with sera from patients without a defined etiological diagnosis of M. pneumoniae infection but with a clinical picture compatible with atypical pneumonia. Noteworthy, the presence of IgG towards EC12 was revealed in serum samples from six patients who received a negative diagnosis of M. pneumoniae infection by the CF test. Moreover, IgG antibodies against the recombinant antigens were detected in sera from seven patients who were not checked for M. pneumoniae infection. By contrast, none of these sera positively reacted with the commercial ELISA, thus, further highlighting the better sensitivity of assays based on recombinant antigens.
Previous studies have demonstrated the clinical usefulness of recombinant antigens for the serological diagnosis of M. pneumoniae infection in humans [22] [23] [24] [25] [26] . Also, the use of recombinant antigens has been evaluated for different types of infections, particularly those regarding veterinary Mycoplasma species [27] [28] [29] . However, the composition of the protein cocktail representative of the M. pneumoniae antigenic repertoire and usable for antibody detection in humans remains an open question. The present study demonstrates that the use of recombinant antigens is effective in distinguishing M. pneumoniae-infected individuals from uninfected individuals and that assays with such antigens have improved performance characteristics compared to those using the whole-cell bacterial antigen, thus, providing the basis of standardized assays for the serodiagnosis of M. pneumoniae diseases.
